The FDA approved Redsyvir's treatment of the new Crown Novarma rare disease drug orphaned.

October 23, 2020 / Medical Information List: FDA approves New Crown for Redsyvir Treatment; Novartis Rare Disease Drug Named Orphan Drug; Roche and Atea work together to develop oral antiviral therapy; Pfizer will acquire Arixa Pharmaceuticals; Takeda Aitbant listing application to be included in priority review ... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Briefing Genetics Office: The approval process is constantly optimized On the evening of October 21, the Genetics Office issued the Notice on Further Optimizing the Administrative Approval Process for Human Genetic Resources, which focuses on two major optimizations: adjusting the time for the submission of ethical review approvals for collection and approval and the time for the submission of ethical review approvals and clinical trial approvals, notifications or filings for international cooperation scientific research.
(China Genetics Office) Henan Provincial Health Insurance Bureau clearly the third batch of national procurement landing time october 22, Henan Provincial Health Insurance Bureau in the official website hung "on the third batch of national organizations to do a good job in centralized procurement and use of drugs related to the work of the notice", clearly will start to implement the third batch of national procurement results on November 20, 2020.
the scope of the drug implementation is the "National List of Selected Supply Varieties in The Central Procurement of Drugs" published by the State Administration (Henan), 55 selected drugs and their supply of 85 product regulations.
(Henan Provincial Health Insurance Bureau) Jiangsu announced 33,000 consumables code October 22, Jiangsu Province Public Resources Trading Center issued the "Provincial Public Resources Trading Center on the publication of five categories of high-value medical supplies products unified coding information notice", the establishment of the district in the standard or shortlisted orthopaedic, general surgery, cardiothoracic surgery, in vitro circulation and blood purification, oral medicine and other five categories of supplies unified coding.
this time announced a total of 32,857 supplies coding information, involving Medtron, Johnson and Johnson, Abbott, Poco, Vico, Lepu, Jianfan biological and other well-known domestic and foreign equipment products.
(Public Resources Trading Center, Jiangsu Province) Part 2 after observation Roche and Atea jointly developed oral antiviral therapy today, Roche and Atea Pharmaceuticals jointly announced that the two sides have reached a cooperation agreement, will jointly develop, produce and promote Atea's research oral antiviral drug AT-527.
it can not only be used as oral therapy to treat hospitalized COVID-19 patients, but also may become the first oral treatment option for non-hospitalized patients.
it also has the potential to be a post-exposure prophylac treatment.
Pfizer will acquire Arixa Pharmaceuticals to advance the development of oral antibiotics on October 22, and Arixa Pharmaceuticals, the next-generation oral antibiotic company that is committed to developing drug-resistant Gloria negative bacterial infections, announced that Pfizer's hospital business has now agreed to acquire Arixa.
the financial terms of the acquisition have not been disclosed.
(Sina Pharmaceutical News) Sanno Pharmaceuticals received $105 million in round D financing today, Sanno Pharmaceuticals announced that the company has just received $105 million round of financing.
round of financing will be jointly led by the original shareholders Spinstone Capital, new investment institutions Watson Bio and Sunshine Fusion Capital.
will be used primarily to develop nucleic acid interference (RNAi) drugs.
2020 Q3 U.S. venture capital financing, CB Insights and PwC jointly released the third quarter of 2020 MoneyTree Report shows that U.S. start-ups through venture capital financing totaled $36.5 billion.
the pharmaceutical and healthcare sectors, with digital medicine, artificial intelligence and medical devices among the emerging sectors with the best growth momentum.
(Creative Exchange) Part 3 Pharmaceutical Information Takeda Aitibant listing application to be included in the priority review today, CDE official website announced that Takeda's acetic acid Aitibant injection listing application is to be included in the priority review.
was developed by Takeda's Shire company to treat acute episodes of hereditary angioedema.
is the third FDA-approved drug to treat hereditary angioedema episodes, having previously been added to the list of new drugs in China that are clinically urgently needed abroad.
(Pharma Mission) FDA approved Redsivir's treatment COVID-October 22, 1910, Gilead announced that the U.S. FDA approved the listing of its antiviral drug Veklury (Remdesivir), which had previously been approved by the FDA for emergency use.
Veklury is currently the only FDA-approved COVID-19 therapy in the United States.
is suitable for the treatment of COVID-19 patients over 12 years of age who weigh at least 40 kg and require hospitalization.
(Pharmaceutical Rubik's Cube) Novarma's rare disease drug Branaplam was awarded the orphan drug title by the FDA on October 21, Novarma announced that the FDA has awarded the drug Branaplam (LMI070) orphan drug for the treatment of Huntington's disease, and the company plans to begin clinical trials of Branaplam IIb in HD patients in 2021.
(Sina Pharmaceutical News) Tianguangshi bio-anti-tumor class 1 new drugs were approved clinically today, CDE official website announced that Tianguang real biology submitted a new class of drugs MIL93 injection to obtain a clinical implied license, adaptation for local late stage or metastasis solid tumor.
MIL93 is a recombinant humanized monoclonal antibody targeting Claudin 18.2, which is intended to be developed for the treatment of Cludin 18.2-positive stomach and pancreatic cancer, according to the prospectus.
(Pharmaceutical Mission) Ocon vision biological cooperation new drug approved clinical today, CDE official website announced that Ocon vision biology and Nicox jointly declared a class 1 new drug NCX470 eye drops to obtain clinical trials implied permission to develop for the reduction of open-angle gla glare or high eye pressure patients in the eye pressure.
(Pharmaceutical Mission) Boan Biodeshu single anti-injection in Europe was approved for clinical practice today, Greenlee Pharmaceutical Group announced that its subsidiary Boan Bio-developed recombinant anti-RANKL all-human monoclonal antibody injection (Deshu monoclonal antibody injection (Deshu mono-injection, LY06006 / LY01011) has been approved by the Federal Institute of Vaccines and Biomedical Sciences of the German Federal Ministry of Health to start clinical trials.
currently, the Dshu single anti-injection has been approved in Europe and the United States to carry out clinical trials, and in China into Phase III/I clinical trials.
New England Journal of Medicine today published a multi-center Phase 2 clinical study led by Professor Robin Fo? of the Italian GIMEMA Collaboration.
dasatinib and immunotherapy blinatumomab as a first-line treatment for adult patients with chromosomal-positive acute lymphoblastic leukemia in Philadelphia, with a median follow-up period of 18 months, the total survival rate and disease-free survival rate was as high as 95% and 88%.
NEJM said the "chemotherapy-free" combination therapy could usher in a new era in the treatment of acute lymphoblastic leukemia.
(Pharmaceutical Mingkangde) Pruitt Pharmaceuticals Sulphate Tebutarin atomized inhalation solution 4 imitation listing application was accepted on October 22, CDE official website data show that four Trump Reiter Pharmaceuticals Sulphate Tebutarin atomized inhalation solution 4 imitation listing application was accepted.
domestic Tebutalin inhaler leader for AstraZenecon.
(Mi Net) recall is out of sale! 7.75 million bottles of Japanese children's medicine recently, Japan's "bread superman children's cold syrup" announced a recall of the shelf life between October this year and July 2023 all products, about 7.75 million bottles.
the recall is that the product did not complete all the quality inspection process before the factory, there are omissions in the middle link.
two articles published recently in the journal Nature, which targets TGF-β, and an anti-antibody-based drug, 4T-Trap, have successfully curbed cancer progress in mice.
researchers believe that pharmacological suppression of TGF-β signals in auxiliary T-cells may be a new type of cancer therapy and a powerful complement to existing cancer immunotherapy.
(Biological Exploration) metformin combined oxygen photodynamics to make triple negative breast cancer cells more likely to "see the light dead" photodynamic therapy is a new treatment for breast cancer.
that oxygen photodynamic therapy can alleviate the problem of lack of oxygen in photodynamic therapy by physically giving oxygen.
metformin is a potential new treatment for triple-negative breast cancer.
study was published recently in the Journal of the Yearbook of Translational Medicine.
(Medical New View point)